Literature DB >> 29282599

Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.

Meera Reghunathan1, Kaitlyn J Kelly1, Mark A Valasek2, Andrew M Lowy1, Joel M Baumgartner3.   

Abstract

BACKGROUND: Mucinous appendiceal tumors (MAT) are rare neoplasms that can metastasize to the peritoneum and often are treated with cytoreductive surgery (CRS) and HIPEC. Pathologic classification and outcomes vary, but standardized histologic definitions are emerging. We sought to evaluate outcomes in this disease after CRS/HIPEC using standardized pathologic criteria.
METHOD: Outcomes of MAT with peritoneal metastases (PM) after CRS/HIPEC from 2007 to 2015 were reviewed at our institution. Standardized histologic categories per WHO and consensus definitions were used: low-grade appendiceal mucinous neoplasm (LAMN), low-grade adenocarcinoma (LGAC), or high-grade adenocarcinoma (HGAC) primary tumors; and acellular mucin (AM), low-grade mucinous carcinoma peritonei (LGMCP), or high-grade mucinous carcinoma peritonei (HGMCP) peritoneal metastases. Cox proportional hazards model was used identify predictors of progression-free survival (PFS) by univariate and multivariate analyses.
RESULTS: A total of 183 patients undergoing 197 CRS/HIPECs were included. Among 75 patients with primary histology review, there were 33 (44.0%) LAMNs, 28 (37.3%) LGACs, and 14 (18.7%) HGACs. Peritoneal histology was benign in 6 (3.0%), AM in 33 (16.8%), LGMCP in 114 (57.9%), and HGMCP in 44 (22.3%). PFS was not reached for AM, 34.3 months for LGMCP, and 16.8 months for HGMCP (p < 0.001). Peritoneal histology predicted PFS on multivariate analysis (hazard ratio 9.82 and 24.60 for LGMCP and HGMCP, respectively, vs. AM, p < 0.001). Among the LGMCP group, CEA and completeness of cytoreduction (CC score) predicted PFS on multivariate analysis.
CONCLUSIONS: Standardized peritoneal histology in patients with PM from MAT predicts PFS and patients with low-grade histology can be further discriminated by CEA and CC score.

Entities:  

Mesh:

Year:  2017        PMID: 29282599     DOI: 10.1245/s10434-017-6310-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Genomic Landscape of Appendiceal Neoplasms.

Authors:  Celina S-P Ang; John Paul Shen; Camille J Hardy-Abeloos; Justin K Huang; Jeffrey S Ross; Vincent A Miller; Miriam T Jacobs; Ingrid L Chen; David Xu; Siraj M Ali; Joel Baumgartner; Andrew Lowy; Paul Fanta; Trey Ideker; Sherri Z Millis; Olivier Harismendy
Journal:  JCO Precis Oncol       Date:  2018-08-08

2.  Overall Survival is More Closely Associated with Peritoneal than Primary Appendiceal Pathological Grade in Pseudomyxoma Peritonei with Discordant Pathology.

Authors:  Ayaz Ahmed Memon; Chintamani Godbole; Tom Cecil; Sanjeev Dayal; Brendan Moran; Alexios Tzivanakis; Faheez Mohamed; Norman J Carr
Journal:  Ann Surg Oncol       Date:  2021-11-03       Impact factor: 5.344

3.  Validation of a Nomogram to Predict Recurrence in Patients with Mucinous Neoplasms of the Appendix with Peritoneal Dissemination After Cytoreductive Surgery and HIPEC.

Authors:  L Martín Román; P Lozano; D Baratti; S Kusamura; M Deraco; W Vásquez; L González Bayón
Journal:  Ann Surg Oncol       Date:  2022-07-25       Impact factor: 4.339

4.  Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience.

Authors:  Giada Munari; Gianluca Businello; Paola Mattiolo; Angelo Paolo Dei Tos; Matteo Fassan; Gianmaria Pennelli; Marta Sbaraglia; Chiara Borga; Salvatore Pucciarelli; Gaya Spolverato; Claudia Mescoli; Francesca Galuppini; Antonio Sommariva; Elena Bellan; Sara Lonardi; Fotios Loupakis; Claudio Luchini
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-12       Impact factor: 4.553

5.  Updated staging and patient outcomes in low-grade appendiceal mucinous neoplasms.

Authors:  Samuel J Ballentine; Jacquelyn Carr; Eliahu Y Bekhor; Umut Sarpel; Alexandros D Polydorides
Journal:  Mod Pathol       Date:  2020-07-29       Impact factor: 7.842

6.  The role of mucin cell-free DNA detection as a new marker for the study of acellular pseudomyxoma peritonei of appendicular origin by liquid biopsy.

Authors:  Damián García-Olmo; Susana Olmedillas-López; Delia Cortés-Guiral; Pedro Villarejo; Irene López Rojo; Héctor Guadalajara; Soledad García Gómez-Heras; Mariano García-Arranz
Journal:  Ther Adv Med Oncol       Date:  2020-06-24       Impact factor: 8.168

7.  Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis.

Authors:  Silvia Pesce; Valerio Belgrano; Marco Greppi; Simona Carlomagno; Margherita Squillario; Annalisa Barla; Mariella Della Chiesa; Stefano Di Domenico; Domenico Mavilio; Lorenzo Moretta; Simona Candiani; Simona Sivori; Franco De Cian; Emanuela Marcenaro
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

8.  Defining stage in mucinous tumours of the appendix with peritoneal dissemination: the importance of grading terminology: systematic review.

Authors:  L Martín-Román; P Lozano; W Vásquez; N Palencia; Y Gómez; M J Fernández-Aceñero; L González-Bayón
Journal:  BJS Open       Date:  2021-07-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.